The Society of British Neurological Surgeons

Neurosurgical National Audit Programme

About Us Cookies Login

Surgeon

Mr Stephen Price BSc MBBS PhD FRCS(Neuro.Surg)
Professional Title Neurosurgeon
GMC Number 4094094
Personal Email stephen.price@addenbrookes.nhs.uk
Secretary Ashley Banks 01223 216780
SBNS Member? Yes

Hospitals

Training


BSc Anatomy and developmental biology with biomedical sciences - University of London, 1991 MBBS - University of London, 1994 FRCS London - 1998 FRCS(Neuro.Surg) - London, 2007 PhD - University of Cambridge, 2007

2008

The Medical College of St Bartholomew's Hospital in the City of London: 1988-1994 Intercalated BSC at University College London: 1990-1

1999-2000: SpR (LAT) Oldchurch Hospital, Romford 2001-2005: SpR Addenbrooke's Hospital Cambridge 2005-2008: Clinical Lecturer in Neurosurgery, Cambridge

Professional Activity


NIHR Clinician Scientist and Honorary Consultant Neurosurgeon with special interest in Neuro-Oncology, Department of Clinical Neurosciences, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. Network Lead for CNS Tumours, Anglian Cancer Network (from March 2013). Director of Studies for Clinical Medicine and Bye-Fellow, Queens’ College, University of Cambridge. Member of the National Cancer Research Institute (NCRI) Brain Tumour Clinical Study Group and Imaging & Technology Subgroup East of England Senate Member and Innovation Lead for the Neuro-Oncology Clinical Reference Group.

Society of British Neurological Surgeons British Neuro-oncology Society European Association of Neuro-oncology Congress of Neurological Surgeons International Society of Magnetic Resonance in Medicine

None

Clinical Activity


Neuro-Oncology with particular interest in management of both high and low grade gliomas. I offer the following services: - 5-ALA guided resection of gliomas - Awake craniotomy - Cortical and subcortical mapping - Advanced imaging for surgical planning with particular interest in diffusion tensor imaging Lead Clinician for Neuro-oncology in the Anglian Cancer Network

Lead Clinician for Neuro-oncology in the Anglian Cancer Network Team.

Research


My group uses advanced multimodal MR and PET imaging to understand the heterogeneity of gliomas (high and low grade) in individual patients. We know that gliomas are among the most heterogeneous tumours but still do not have a method of detecting this heterogeneity. Tissue markers cannot impact surgically based therapies. Imaging provides a non-invasive method of assessing tumour pathology. My work focuses on two areas: 1. Intertumoural heterogeneity (i.e. differences between individuals). Especially heterogeneity of tumour invasion. Post-mortem studies show there is variation in tumour invasion with 20-25% of GBMs extend 3 centimetres. 2. Intratumoural heterogeneity (i.e. differences within a tumour in an individual patient). Our work studies variation of response to chemotherapy/radiotherapy and drug uptake. We are developing [3-N-11C-methyl]-temozolomide a PET tracer to correlate response with drug uptake.

1.     C Li, S Wang, J-L Yan, RJ Piper, H Liu, T Torheim, H Kim, NR Boonzaier, R Sinha, T Matys, F Markowetz and SJ Price(2018) Intratumoral heterogeneity of glioblastoma infiltration revealed by joint histogram analysis of diffusion tensor imaging. Neurosurgery(accepted 17 May 2018).

2.     NR Boonzaier, TJ Larkin, T Matys, A van der Hoorn, J-L Yan, and SJ Price(2017) Multiparametric MRI assessment of diffusion and perfusion in contrast-enhancing and non-enhancing components in glioblastoma. Radiology284(1):180-190.

3.     SJ Price, K Allinson, H Liu, NR Boonzaier, J-L Yan, VC Lupson and TJ Larkin (2017) IDH-1 mutated glioblastomas have a less invasive phenotype than IDH-1 wild type glioblastomas: a diffusion tensor imaging study. Radiology283(1):215-221.

4.     J-L Yan, A van der Hoorn, TJ Larkin, NR Boonzaier, T Matys, SJ Price(2017) Extent of resection of peritumoural DTI abnormality as a predictor of survival in adult glioblastoma patients. Journal of Neurosurgery 126(1):234-241.

5.     SJ Price, Young AM, Scotton WJ, J Ching, LA Mohsen, NR Boonzaier, VC Lupson, JR Griffiths, MA McLean and TJ Larkin (2016) Multimodal MRI can identify perfusion and metabolic changes in the invasive margin of glioblastomas. Journal of magnetic resonance imaging 43(2): 487–494.

Outcome Report

SBNS
Understanding activity pie charts


What does the Consultant activity pie chart show?

The Consultant activity pie charts represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.

Please note that for Consultants who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.

Elective Procedural Case-mix and Case Volume
Image

SBNS
Understanding mortality funnel plot charts

What does the Consultant funnel plot chart show?

The Hospital Consultant mortality funnel plot represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.

The mortality presented here is for three years: April 2014 – March 2017. Please note that for Consultant who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.

The horizontal yellow line represents the national average mortality. The solid black lines above and below the yellow line are the control limits. The upper control limit represents the highest expected mortality rate. The Consultant's outcome is highlighted in magenta.

30 Day Risk Adjusted Elective Procedural Mortality
Image

The outcomes of this consultant are within the expected range

Understanding the risk-adjusted mortality rate

Risk adjustment (or case-mix adjustment) takes into account patient risk factors to calculate a predicted mortality rate. This means that hospitals or consultants who see higher risk patients have their mortality rate adjusted to account for the factors that put these patients at greater risk.

Understanding the 'funnel plot' diagram

The funnel plot displays the risk-adjusted elective procedural mortality ratio for each consultant plotted against the expected number of mortalities for that consultant. The expected number of mortalities for each consultant will vary depending on the number of procedures they have performed and the risk profile of the patients they have treated. The horizontal yellow line represents the expected ratio. The solid black line above the chart is known as a ‘control limit’. This control limit represents the highest expected mortality rate. Risk-adjusted rates appearing beneath this line are within the normal range.

Back to Surgeons List